This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.

Start Date01 Dec 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT07715279

/ RecruitingPhase 2IIT

Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (VERIFICATION Study)

Calcific aortic valve stenosis (CAVS) is a condition in which the aortic valve progressively narrows and stiffens due to calcium deposition, eventually impairing blood flow from the heart to the body. No drug therapy has been proven to slow CAVS progression. Individuals with mild-to-moderate CAVS are managed with periodic monitoring until the stenosis becomes severe, at which point surgical or transcatheter valve replacement is the only treatment option. The goal of this clinical trial is to determine whether vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, can slow the progression of mild-to-moderate CAVS.
The primary questions this study aims to answer are:
Does vericiguat slow the progression of aortic valve calcium accumulation, as measured by the change in aortic valve calcium score from baseline to 24 months, compared to placebo?
The study will compare vericiguat against a placebo (an inactive pill that is identical in appearance but contains no active drug). Both participants and the research team will not know which treatment each participant is receiving throughout the study.
Participants will:
Take vericiguat or placebo orally once daily for 24 months; Begin treatment at 2.5 mg/day and undergo a stepwise dose increase every two weeks to a target dose of 10 mg/day, provided the drug is tolerated; Attend approximately 8 scheduled study visits over two years, during which they will undergo cardiac imaging examinations (transthoracic echocardiography and non-contrast cardiac CT), blood sample collection, physical assessment, and completion of standardized questionnaires on quality of life and heart failure symptoms; Undergo cardiac magnetic resonance imaging (MRI) at the beginning and end of the study, if there are no contraindications.
Approximately 238 participants will be enrolled across roughly 19 hospitals in China.

Start Date24 Sep 2026

Sponsor / Collaborator

West China Hospital

[+1]

DRKS00040134

/ SuspendedNot Applicable

Register-based study of vericiguat in patients with advanced heart failure: effects on pulmonary vasculopathy, right-sided heart failure and mortality following heart transplantation (VeriHTX) - VeriHTX

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Vericiguat

100 Translational Medicine associated with Vericiguat

100 Patents (Medical) associated with Vericiguat

398

Literatures (Medical) associated with Vericiguat

01 Nov 2026·TALANTA

Comprehensive study on the forced degradation impurities of vericiguat with high-resolution LC-MS/MS and 1D/2D-NMR

Article

Author: Ding, Lei ; Sun, Cuirong ; Zhang, Ruochen ; Lin, Jinsheng ; Deng, Wenchan ; Liu, Shuangshuang ; Chen, Feifei

Vericiguat (VER), a novel soluble guanylate cyclase agonist for heart failure, was subjected to comprehensive forced degradation studies to assess its stability and elucidate degradation pathways. The study was conducted in accordance with ICH guidelines, including alkaline, acidic, oxidative, photolytic, and thermal stress conditions. And tentatively structural identification of degradation impurities was carried out using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The results indicated that VER was susceptible to degradation under alkaline (NaOH) and hydrogen peroxide (H₂O₂) oxidative conditions, yielding nine degradation impurities (DIs 1-7, 9, 10). Among these, eight have not been previously reported, with the exception of DI-7. Moreover, under a newly introduced free-radical oxidation condition using benzoyl peroxide (BPO), two additional novel impurities (DI-8 and DI-11) were generated. And two major degradants (DI-3-2 and DI-5) were isolated and their structures were confirmed by 1 Dimension/2 Dimension-Nuclear Magnetic Resonance (1D/2D-NMR) analysis. Based on the structures of the degradation impurities, the degradation pathways were elucidated and the molecular stability was investigated. The results demonstrate that the primary degradation mechanisms involved pyrimidine ring cleavage, oxidation of the amino group, hydrolysis of ester and amide bonds, as well as intramolecular cyclization and rearrangement. This study successfully established a comprehensive impurity profile for VER and provided robust scientific data for formulating its quality standards, thereby supporting stability assessment and quality control during pharmaceutical development.

01 Nov 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Intrarenal venous flow improvement after vericiguat in worsening HFrEF: A prospective VExUS-based study

Article

Author: Severino, Paolo ; Segato, Camilla ; Brigato, Claudia ; D'Amato, Andrea ; Cusumano, Gabriele ; Gigante, Antonietta ; Cianci, Rosario ; Vizza, Carmine Dario ; Cascone, Rosa ; Myftari, Vincenzo ; Giovagnoli, Francesco ; Germanò, Rosanna

BACKGROUND:

In patients with heart failure with reduced ejection fraction (HFrEF) and recent worsening despite guideline-directed medical therapy (GDMT), vericiguat reduces adverse cardiovascular events. However, its effects on systemic venous congestion assessed by the Venous Excess Ultrasound (VExUS) protocol remain unclear. We aimed to evaluate changes in VExUS parameters after vericiguat initiation and identify predictors of intrarenal venous flow (IRVF) normalization.

METHODS:

In this single-center prospective observational study, consecutive patients eligible for vericiguat were enrolled. Clinical, laboratory, and VExUS assessments, including inferior vena cava, lung B-lines, jugular venous distension, hepatic vein Doppler flow, and IRVF, were performed at baseline and after 6 months. Renal resistive index (RRI) was also measured.

RESULTS:

42 patients (mean age 72.5 ± 9.7 years; 81.0% male) were included. At follow-up, IRVF was the only VExUS parameter showing significant improvement, with an increase in continuous patterns (p = 0.021). In multivariable analysis, vericiguat therapy and higher estimated glomerular filtration rate (eGFR) were independently associated with continuous IRVF (p < 0.001), whereas RRI ≥0.70 and abnormal hepatic venous flow predicted discontinuous IRVF.

CONCLUSIONS:

IRVF was the most sensitive VExUS parameter and improved after vericiguat in worsening HFrEF. These findings suggest a potential beneficial effect of vericiguat on renal venous congestion and cardiorenal hemodynamic.

01 Oct 2026·JOURNAL OF APPLIED TOXICOLOGY

Effects of Sacubitril Valsartan Combined With Vericiguat on NT‐proBNP and CK‐MB Levels in Patients With Chronic Heart Failure

Article

Author: Jin, Lijuan ; Yang, Tingting

ABSTRACT:

This study aims to probe the influence of sacubitril valsartan sodium tablets combined with vericiguat on N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and creatine kinase isoenzyme (CK‐MB) levels in patients with chronic heart failure (CHF). One hundred and twenty CHF patients were enrolled and stratified into a control group (sacubitril valsartan sodium tablets) and a combination group (sacubitril valsartan sodium tablets + vericiguat). Outcome measures included New York Heart Association (NYHA) functional class shifts, echocardiographic indices, cardiac injury markers, 6‐min walk distance (6MWD), endothelial function parameters, inflammatory mediator levels, and adverse clinical events. Following a 6‐month treatment period, patients in the combination group exhibited superior functional improvement, as reflected by greater advancement in NYHA class. Echocardiographic evaluation revealed more favorable ventricular remodeling in this group, with reduced left ventricular end‐diastolic and end‐systolic diameters and an elevated ejection fraction. The combination group had a higher 6MWD. Biomarker analysis showed lower NT‐proBNP and CK‐MB levels in the combination group. Furthermore, improvements in endothelial function were noted, with decreased endothelin and elevated NO, NOS, and CGRP levels in the combination group. Markers of systemic inflammation, including CRP and IL‐6, were also attenuated in the combination group. The incidence of adverse reactions and cardiovascular events did not differ significantly between the groups. Co‐administration of sacubitril/valsartan and vericiguat enhances cardiac performance, optimizes vascular endothelial responsiveness, modulates heart failure–related biomarkers, and mitigates inflammatory activity in patients with CHF without increasing the risk of adverse events.

News (Medical) associated with Vericiguat

14 May 2026

·firstwordpharma.com

Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital

Rigel gets hands on Pfizer's recently-approved breast cancer drug Bayer cuts early-stage assets from pipeline Superior weight loss in Wegovy HD early responders 'First-of-its-kind' collab aims to incubate new biotechs Rigel gets hands on Pfizer's recently-approved breast cancer drug Having signalled their intent last year to find a US commercialisation partner for vepdegestrant, Pfizer and Arvinas reached an agreement with Rigel Pharmaceuticals on Tuesday to both market and further develop the PROTAC oestrogen receptor (ER) degrader. The deal comes a matter of weeks after the FDA approved the oral drug as Veppanu for ER-positive, HER2-negative, advanced or metastatic breast cancer in adults carrying ESR1 mutations and who have progressed after at least one line of endocrine therapy (see – Spotlight On: Uncertain future resolved for Pfizer and Arvinas' once heavily touted breast cancer drug as Rigel steps in). Under the agreement, Pfizer and Arvinas will receive $85 million in upfront and transition payments, with the potential for a further $320 million in development, regulatory and commercial milestones, plus tiered sales royalties in the mid-teens to mid-20s. All payments from Rigel will be split evenly between the two companies. Pfizer itself had paid Arvinas $650 million upfront in 2021 to co-develop and co-commercialise vepdegestrant, but subsequent clinical readouts narrowed the addressable patient population. For its part, Rigel will own global rights to vepdegestrant, allowing it to sublicense the therapy to potential partners for development and marketing outside of the US. -Matt Dennis Bayer cuts early-stage assets from pipeline As part of its first-quarter earnings report Tuesday, Bayer disclosed that it has cut two Phase I programmes from its pipeline and halted development of Verquvo (vericiguat) in adults with stable chronic heart failure (CHF) and reduced ejection fraction (HFrEF). In September, the pharma, alongside partner Merck & Co., reported that the sGC stimulator — approved in the US and EU for certain patients with worsening CHF — failed to meet its primary endpoint in a Phase III trial for HFrEF. The axed early-stage assets include BAY 2701250, an atrial natriuretic peptide (ANP)-based candidate that was in Phase I testing for pulmonary hypertension. According to ClinicalTrials.gov, the 82-person study finished last May. The third cut programme is BAY 3178275, a Phase I-stage GPR84 antagonist being developed for diabetic neuropathic pain.-Elizabeth Eaton Superior weight loss in Wegovy HD early responders New sub-analyses from the pivotal STEP UP trial show Novo Nordisk's 7.2-mg semaglutide injectable formulation (marketed as Wegovy HD) resulted in a ~28% weight loss among 'early responders' — outclassing the 20.7% reduction originally seen in the wider study. Data presented Tuesday at the European Congress on Obesity (ECO) revealed that early responders — defined as those achieving ≥15% body weight loss within 24 weeks — accounted for 27% of Wegovy HD recipients, compared with 21% for the 2.4-mg dose and 3% on placebo. Novo said that the early responders on Wegovy HD lost on average 27.7% of their weight by week 72, versus. Moreover, a separate MRI sub-analysis with STEP-UP confirmed that 84% of weight lost was attributable to fat mass reduction, including a >30% decrease in abdominal visceral fat, with muscle function largely preserved. For further analysis, see — Spotlight On: Early responder analysis could be useful catalyst for Wegovy HD in US obesity showdown. -Pavan Kamat 'First-of-its-kind' collab aims to incubate new biotechs In what is being touted as a "first-of-its-kind" collaboration, life sciences investment firm Delos Capital is partnering with biopharmaceutical company AP Biosciences to create and incubate new biotechs. The tie-up combines Delos' company-building expertise with APBio's antibody discovery platforms in an effort to accelerate novel medicines through clinical proof of concept. The collaboration will also take advantage of APBio's operational efficiency in Greater China, which the parties noted enables "faster and more capital-efficient translation from innovative concepts to clinical-stage assets." The companies will initially focus on autoimmune diseases using bi- and tri-specific antibody approaches that combine novel and de-risked targets and mechanisms, with Delos — through its Delos Foundry — leading therapeutic ideation, financing and strategic development. "This collaboration allows us to extend the impact of our antibody discovery platforms beyond our internal pipeline," said Jeng Her, APBio's chief executive. Meanwhile, Henry Chen, founder and managing partner of Delos noted that "if we don't see existing companies that match one of our investment theses, our team can fill that gap by incubating innovative assets in a US-based NewCo." -Matt Dennis The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

06 May 2026

·www.biospace.com

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6 th May 2026 Immutrin Ltd, (“Immutrin” or “the Company”) a biotechnology company developing next generation antibody therapy to reverse amyloidosis, today announces the appointment of Dr Robert Blaustein, MD, PhD as Chief Medical Officer (CMO). The Company also announces the establishment of its US subsidiary. Robert brings extensive experience in cardiovascular clinical research and drug development, with a proven track record of advancing innovative therapeutics from early development through regulatory filing and approval. He will build out Immutrin’s clinical team and lead the Company’s clinical development and regulatory strategy as it advances towards first-in-human studies. “ Appointing our Chief Medical Officer marks a pivotal milestone for Immutrin as we evolve into a clinical-stage organization ,” said Mihriban Tuna, Chief Executive Officer at Immutrin . “ Robert’s deep expertise in cardiovascular medicine and proven leadership in clinical development will be instrumental as we advance our lead asset towards first-in-human studies .” Prior to joining Immutrin, Robert served as Chief Development Officer at Edgewise Therapeutics, where he led development of the novel cardiac sarcomere modulator EDG-7500 and oversaw the company’s broader cardiovascular clinical stage pipeline. Earlier in his career, he spent more than 15 years at Merck, where he led late-stage development programs in atherosclerosis and heart failure. Notably, he led the vericiguat development team through the successful completion of the Phase 3 VICTORIA heart failure trial, as well as the subsequent regulatory filing and global approval of vericiguat for patients with worsening heart failure, in collaboration with Bayer. Robert earned his undergraduate degree in mathematics from Wesleyan University. He completed his MD/PhD training at Albert Einstein College of Medicine, medical residency at Brigham and Women’s Hospital, and cardiology fellowship at Massachusetts General Hospital. Following, an HHMI postdoctoral fellowship in the Department of Biochemistry at Brandeis University, he then served on the faculty at Tufts Medical Center before transitioning to industry with Merck. “ I am excited to join Immutrin at such an important stage of its journey ,” said Dr. Blaustein, Chief Medical Office at Immutrin. “While current therapies for amyloidosis can slow disease progression, they do not remove existing amyloid deposits. The Company’s novel antibody approach, designed to selectively target and clear deposited amyloid, offers a promising strategy to address the underlying pathology. I look forward to advancing this innovative therapy into clinical development .” In parallel with this leadership appointment, Immutrin has established a US subsidiary, Immutrin US Inc., to support planned clinical activities in North America. ENDS About Immutrin Immutrin is a biotechnology company developing the next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils. Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys, FRS; Nobel Laureate Sir Gregory Winter, FRS; and Professor Daniel Christ and is built on decades of scientific and clinical leadership in amyloidosis combined with groundbreaking antibody expertise in drug development. Immutrin is led by an experienced management team and supported by other leading global investors including Frazier Life Sciences, F-Prime, Qiming Venture Partners and SR One. For more information visit . For media inquiries, please contact: ICR Healthcare Mary-Jane Elliott / Sarah Elton-Farr/ Stephanie Cuthbert immutrin@icrinc.com Tel: +44 (0) 20 3709 5700

Executive Change

04 Sep 2025

·www.prnewswire.com

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Phase 1

100 Deals associated with Vericiguat

External Link

KEGG	Wiki	ATC	Drug Bank
D11051	Vericiguat	C01DX	DB15456

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Reduced ejection fraction co-occurrent and due to chronic heart failure	China	Bayer AG	18 May 2022
Chronic heart failure	European Union	Bayer AG	16 Jul 2021
Chronic heart failure	Iceland	Bayer AG	16 Jul 2021
Chronic heart failure	Liechtenstein	Bayer AG	16 Jul 2021
Chronic heart failure	Norway	Bayer AG	16 Jul 2021
Heart Failure	United States	Merck Sharp & Dohme LLC	19 Jan 2021
Shock	United States	Merck Sharp & Dohme LLC	19 Jan 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Left ventricular systolic dysfunction	Phase 3	Brazil	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Canada	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Denmark	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	France	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Germany	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Italy	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Netherlands	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	South Korea	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Spain	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Sweden	Merck Sharp & Dohme LLC	31 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2026	Not Applicable	-	41	Vericiguat	ehmzzlrpyj(teaxurmyyh) = uhrbfmpufr qzyhawoxmu (hsrtsxwgwd ) View more	Positive	31 Aug 2026
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	732	Vericiguat (VICTORIA-like)	witzchbdqk(dnwugyewgb) = xfydiwxboi llnawksukq (fmpdcdofos ) View more	Positive	29 Aug 2026
				Vericiguat (VICTOR-like)	witzchbdqk(dnwugyewgb) = pfvicfmhtf llnawksukq (fmpdcdofos ) View more
OpTIMa-HF (ESC2026)	Not Applicable	Heart failure with reduced ejection fraction	685	Vericiguat	oxjbhgqyys(eakvfydhll) = ylovporail ustunofvji (mlhqslbyaw ) View more	Positive	28 Aug 2026
VICTOR (ESC2026)	Phase 3	Heart Failure	6,105	Vericiguat	avbnpgtbow(ybtckvljcq) = kptjtflnjd qhbuvmgxbq (bxkjhdgvrb ) View more	Positive	28 Aug 2026
				Placebo	avbnpgtbow(ybtckvljcq) = oeemseducb qhbuvmgxbq (bxkjhdgvrb ) View more
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	212	Vericiguat	hdhrhqmjqq(fjzikzlmth) = lnnweoblsg pxyswmnxdq (knwrgyisnw ) View more	Positive	11 May 2026
VERISEC (ESC2026)	Not Applicable	Heart Failure	835	Vericiguat	tjxhbymqil(bmpumhjahv) = thlfiyrnyx kapoyyphqa (runsllwkyl, 1.07) View more	Positive	10 May 2026
OPTIMA-HF (ESC2026)	Not Applicable	Heart Failure	572	Vericiguat (<75 years)	rgakdluuot(egkgywaswg) = vlfzcuxtbz bmhkfabdfx (nockvcsfgl ) View more	Positive	10 May 2026
				Vericiguat (≥75 years)	rgakdluuot(egkgywaswg) = osdytsryst bmhkfabdfx (nockvcsfgl ) View more
NCT05420012 (Pubmed \| Am J Cardiol)	Phase 2	Heart failure with reduced ejection fraction	26	Vericiguat	ezommrovdk(idsdwpyjgm): Difference (%) = 0.7 (95.0% CI, -1.1 to 2.5), P-Value = 0.4 View more	Positive	01 Feb 2026
				Placebo
NCT05711719 (CTgov)	Phase 2	Metabolic Syndrome \| Coronary microvascular dysfunction \| Anomalous Left Coronary Artery	45	Vericiguat (Vericiguat)	mrqkuwbltj(ahwwnptjei) = xpuwldiugh uvqzscbbrx (ofxtmdbncf, 1.28) View more	-	27 Jan 2026
				Placebo (Placebo)	mrqkuwbltj(ahwwnptjei) = ehzxtrqdjr uvqzscbbrx (ofxtmdbncf, 1.18) View more
NCT05093933 (VICTOR \| MK-1242-035, CTgov)	Phase 3	Reduced ejection fraction co-occurrent and due to chronic heart failure \| Chronic heart failure	6,106	Vericiguat (Vericiguat)	tzdvlqsfpx = tcbpaqhhnl eijwebhuar (vkrjvlaoez, yrgvlvebqb - nmlccufhlv) View more	-	19 Dec 2025
				Placebo (Placebo)	tzdvlqsfpx = bpkrdnemna eijwebhuar (vkrjvlaoez, emrnjgpegm - dokgblaqta) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis